Global Market Insights on Precision Medicine (2020-2026): Emphasis on Technology (Big Data Analytics, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Others), Disease Area (Oncology, Respiratory Diseases, Central Nervous System Disorders, Immunology, Genetic Diseases, Others), End-user (Hospitals & Clinics, Pharmaceuticals, Diagnostic Companies, Healthcare IT Firms, Others) and Region/Country
- UNI4065925
- 276 Pages
- August 2020
- Pharmaceuticals
Precision medicine (PM) is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. Medicine involving a drug selection and dosage profiling in combination with clinical and molecular biomarkers can ensure the maximal efficacy and safety of the treatment. The major hindrance toward the development of such therapies is the handling of the “Big Data,” to keep the databases updated. Robust automated data mining tools are being developed to extract information regarding genes, variations, and their association with diseases.
Phenotyping, an integral part of PM, is aimed at translating the data generated at cellular and molecular levels into clinically relevant information. Precision Medicine Moves Care from Population-Based Protocols to Truly Individualized Medicine as President of the US announced the Precision Medicine Initiative in his 2015 State of the Union address. Under the initiative, medical care would transition from a one-size-fits-all approach to an individualized approach, in which data on each patient’s genomic makeup, environment, and lifestyle (the exposome) helps medical professionals tailor treatment and prevention strategies. To achieve the Precision Medicine Initiative mission statement, “to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care,” researchers and clinicians need vast and varied amounts of data and the technology to ensure that data is widely accessible and usable.
Hoffmann-La Roche, Eli Lilly and Company, NeoGenomics Laboratories, Novartis, Teva Pharmaceutical, Thermo Fisher Scientific, Quest Diagnostics, Abbott Laboratories, NanoString Technologies, and AstraZeneca are some of the prominent players operating in the global precision medicine market. Several M&A’s along with partnerships have been undertaken by these players to facilitate costumers with hi-tech and innovative products.
Insights Presented in the Report
“Amongst Technology, Drug Discovery segment holds the major share”
Based on technology type, the market is fragmented into big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others. Drug discovery dominated the market with a share of 23.3% in 2019. Recent technological and analytical advances in genomics, have now it possible to rapidly identify and interpret the genetic variation underlying a single patient’s disease, thereby providing a window into patient-specific mechanisms that cause or contribute to disease, which could ultimately enable the ‘precise’ targeting of these mechanisms. Precision medicine can target several diseases.
“Amongst Disease Area, Oncology is expected to dominate the market during the analyzed period”
Based on the market segment by application type, the market is segmented into oncology, respiratory diseases, central nervous system disorders, immunology, genetic diseases, and others. With the advent of precision medicine, cancer treatment is moving from a paradigm in which treatment decision is primarily based on tumor location and histology followed by molecular information to a new paradigm whereby treatment decisions will be primarily based on molecular information followed by histology and tumor location. Oncology attained a maximum share of 54% in 2019.
“Amongst End-user, Pharmaceuticals is expected to dominate the market during the analyzed period”
Based on the market segment by end-user, the market is fragmented into hospitals & clinics, pharmaceuticals, diagnostic companies, Healthcare-IT firms, and others. The precision medicine suppliers that understand the technology and the goals of value-based healthcare can create value in the precision medicine value-chain by offering value-based solutions and platforms to interpret and connect data points. Pharmaceutical has dominated the market with a market share of 47% in 2019.
“United States represents one of the largest markets of Precision Medicine market”
For a better understanding on the market dynamics of the Precision Medicine market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and Rest of North America), Europe (Germany, France, Spain, Italy, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia and Rest of APAC) and rest of the world has been conducted. United States generated revenue of US$ 17.9 billion in 2019. The United States has the largest market for Precision Medicine due to high awareness.
Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts
• The report presents a quick review of overall industry performance at one glance
• The report covers in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
• The study comprehensively covers the market across different segments
• The report comprises of review on the precision medicine as a future in healthcare, its business model, and precision medicine in the COVID-19 management
• Deep dive regional level analysis of the industry
Customization Options:
The precision Medicine Market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1.1 Market Definition 20
1.2 Objective of the Study 20
1.3 Limitation 20
1.4 Stakeholders 21
1.5 Currency used in the Report 21
1.6 Scope of the Global Precision Medicine Market Study 21
2. RESEARCH METHODOLOGY OR ASSUMPTION 22
2.1 Research Methodology for the Precision Medicine Market Study 22
2.1.1 Main objective of the Precision Medicine Market Study 23
3. INDUSTRY PERFORMANCE 24
4. EXECUTIVE SUMMARY 25
5. MARKET OVERVIEW 27
5.1 Introduction 27
5.1.1 The progress in five specific areas will fuel this acceleration: 28
5.2 Market Dynamics 29
5.2.1 Market Trend & Drivers 29
5.2.1.1 Rise in Demand for Preventive Care 29
5.2.1.2 Advancements in Sequencing Technologies 31
5.2.2 Market Challenges 32
5.2.2.1 Unstable Legal and Regulatory Framework 32
5.2.2.2 Lack of Access to Relevant Data 32
5.2.3 Market Opportunities 33
5.2.3.1 Targeted Gene Therapies 33
5.2.3.2 Rising Awareness Regarding Modified Medications along with Lifestyle Changes 34
6. PRECISION MEDICINE AS A FUTURE IN HEALTHCARE 36
6.1 General Overview 36
6.2 Digital ecosystems of the future 36
6.3 Digital platforms fuelled by cognitive technology 37
6.4 The solution: precision medicine 37
6.5 Breaking barriers to health data 38
6.6 Patient-centric: leapfrogging with personalized medicine 39
6.7 The future of precision medicine 39
7. BUSINESS MODEL OF PRECISION MEDICINE 40
7.1 Introduction 40
7.1.1 Data 40
7.1.2 Individualized Impact 41
7.1.3 Business Model 43
7.1.4 Partnership 44
8. PRECISION MEDICINE FOR COVID-19 MANAGEMENT 46
8.1 Introduction 46
8.1.1 Available Therapies 47
8.1.2 Trial Design 48
8.1.3 Precision Medicine Initiatives Regarding COVID-19 50
9. LEGAL & REGULATORY FRAMEWORK 51
9.1 General Overview 51
9.1.1 United States 51
9.1.1.1 Next-Generation Sequencing (NGS) Tests 51
9.1.1.2 Co-development 52
9.1.1.3 The FDA's Role in Advancing Precision Medicine 53
9.1.1.4 Clinical Databases Guidance 54
9.1.1.5 Analytical Validation Guidance 54
9.1.1.6 FDA's Bioinformatics Platform 54
9.2 Coverage and Payment Policy 55
9.3 Value Assessment Frameworks 55
9.4 The Changing Reimbursement Landscape for Diagnostics 56
9.5 Value-Based Payment Models 56
9.6 Europe 56
9.7 Japan 57
9.7.1 Research-Based Genome Screening in Japan 58
9.7.2 Arrangements of Infrastructure for Precision Medicine in Japan 60
9.8 Australia 61
9.8.1 Safety and Regulation 61
10. DEMAND AND SUPPLY SIDE ANALYSIS 63
10.1 Demand Side Analysis 63
10.2 Supply Side Analysis 64
10.2.1 Top Product Launches 66
10.2.2 Top Business Partnerships 72
10.2.3 Business Expansion, Investment, and Divestitures 75
10.2.4 Top Mergers and Acquisitions 77
11. VALUE CHAIN ANALYSIS 80
11.1 Value Chain Analysis 80
12. MARKET INSIGHTS BY TECHNOLOGY 82
12.1 General Overview 82
12.1.1 Big Data Analytics 83
12.1.2 Bioinformatics 84
12.1.3 Gene Sequencing 86
12.1.4 Drug Discovery 88
12.1.5 Companion Diagnostics 92
12.1.6 Other Technologies 94
13. MARKET INSIGHTS BY DISEASE-AREA 97
13.1 General Overview 97
13.1.1 Oncology 99
13.1.2 Respiratory Diseases 100
13.1.3 Central Nervous System Disorders 103
13.1.4 Immunology 106
13.1.5 Genetic Diseases 109
13.1.6 Other Disease Areas Precision Medicine 111
14. MARKET INSIGHTS BY END-USER 116
14.1 General Overview 116
14.1.1 Hospitals & Clinics 118
14.1.2 Pharmaceuticals 121
14.1.3 Diagnostic Companies 123
14.1.4 Healthcare IT Firms 126
14.1.5 Other End-Users 128
15. MARKET INSIGHTS BY REGION 130
15.1 General Overview 130
15.2 North America Precision Medicine Market 132
15.2.1 North America Precision Medicine Market, by Technology 133
15.2.2 North America Precision Medicine Market, by Disease-Area 133
15.2.3 North America Precision Medicine Market, by End-User 134
15.2.4 North America Precision Medicine Market, by Country 134
15.2.4.1 The United States Precision Medicine Market 135
15.2.4.1.1 US Precision Medicine Market, by Technology 137
15.2.4.1.2 US Precision Medicine Market, by Disease-Area 137
15.2.4.1.3 US Precision Medicine Market, by End-User 138
15.2.4.2 Canada Precision Medicine Market 138
15.2.4.2.1 Canada Precision Medicine Market, by Technology 141
15.2.4.2.2 Canada Precision Medicine Market, by Disease-Area 141
15.2.4.2.3 Canada Precision Medicine Market, by End-User 142
15.2.4.3 Mexico Precision Medicine Market 142
15.2.4.3.1 Mexico Precision Medicine Market, by Technology 143
15.2.4.3.2 Mexico Precision Medicine Market, by Disease-Area 144
15.2.4.3.3 Mexico Precision Medicine Market, by End-User 144
15.2.4.4 Rest of North America Precision Medicine Market 145
15.2.4.4.1 Rest of North America Precision Medicine Market, by Technology 146
15.2.4.4.2 Rest of North America Precision Medicine Market, by Disease-Area 146
15.2.4.4.3 Rest of North America Precision Medicine Market, by End-User 147
15.3 Europe Precision Medicine Market 148
15.3.1 Europe Precision Medicine Market, by Technology 149
15.3.2 Europe Precision Medicine Market, by Disease-Area 150
15.3.3 Europe Precision Medicine Market, by End-User 150
15.3.4 Europe Precision Medicine Market, by Country 151
15.3.4.1 Germany Precision Medicine Market 151
15.3.4.1.1 Germany Precision Medicine Market, by Technology 154
15.3.4.1.2 Germany Precision Medicine Market, by Disease-Area 154
15.3.4.1.3 Germany Precision Medicine Market, by End-User 155
15.3.4.2 The United Kingdom Precision Medicine Market 155
15.3.4.2.1 United Kingdom Precision Medicine Market, by Technology 157
15.3.4.2.2 The United Kingdom Precision Medicine Market, by Disease-Area 158
15.3.4.2.3 United Kingdom Precision Medicine Market, by End-User 158
15.3.4.3 France Precision Medicine Market 159
15.3.4.3.1 France America Precision Medicine Market, by Technology 160
15.3.4.3.2 France Precision Medicine Market, by Disease-Area 161
15.3.4.3.3 France Precision Medicine Market, by End-User 161
15.3.4.4 Italy Precision Medicine Market 162
15.3.4.4.1 Italy Precision Medicine Market, by Technology 163
15.3.4.4.2 Italy Precision Medicine Market, by Disease-Area 164
15.3.4.4.3 Italy Precision Medicine Market, by End-User 164
15.3.4.5 Spain Precision Medicine Market 165
15.3.4.5.1 Spain Precision Medicine Market, by Technology 167
15.3.4.5.2 Spain Precision Medicine Market, by Disease-Area 167
15.3.4.5.3 Spain Precision Medicine Market, by End-User 168
15.3.4.6 Rest of Europe Precision Medicine Market 168
15.3.4.6.1 Rest of Europe Precision Medicine Market, by Technology 170
15.3.4.6.2 Rest of Europe Precision Medicine Market, by Disease-Area 171
15.3.4.6.3 Rest of Europe Precision Medicine Market, by End-User 171
15.4 Asia-Pacific Precision Medicine Market 172
15.4.1 Asia-Pacific Precision Medicine Market, by Technology 174
15.4.2 Asia-Pacific Precision Medicine Market, by Disease-Area 175
15.4.3 Asia-Pacific Precision Medicine Market, by End-User 175
15.4.4 Asia-Pacific Precision Medicine Market, by Country 176
15.4.4.1 China Precision Medicine Market 176
15.4.4.1.1 China Precision Medicine Market, by Technology 179
15.4.4.1.2 China Precision Medicine Market, by Disease-Area 179
15.4.4.1.3 China Precision Medicine Market, by End-User 180
15.4.4.2 Japan Precision Medicine Market 180
15.4.4.2.1 Japan Precision Medicine Market, by Technology 183
15.4.4.2.2 Japan Precision Medicine Market, by Disease-Area 184
15.4.4.2.3 Japan Precision Medicine Market, by End-User 184
15.4.4.3 India Precision Medicine Market 185
15.4.4.3.1 India America Precision Medicine Market, by Technology 186
15.4.4.3.2 India Precision Medicine Market, by Disease-Area 187
15.4.4.3.3 India Precision Medicine Market, by End-User 187
15.4.4.4 Australia Precision Medicine Market 188
15.4.4.4.1 Australia Precision Medicine Market, by Technology 190
15.4.4.4.2 Australia Precision Medicine Market, by Disease-Area 190
15.4.4.4.3 Australia Precision Medicine Market, by End-User 191
15.4.4.5 Rest of Asia-Pacific Precision Medicine Market 191
15.4.4.5.1 Rest of Asia-Pacific Precision Medicine Market, by Technology 192
15.4.4.5.2 Rest of Asia-Pacific Precision Medicine Market, by Disease-Area 193
15.4.4.5.3 Rest of Asia-Pacific Precision Medicine Market, by End-User 193
15.5 Rest of World Precision Medicine Market 194
15.5.1 Rest of World Precision Medicine Market Size by Technology 195
15.5.2 Rest of World Precision Medicine Market Size by Disease-Area 196
15.5.3 Rest of World Precision Medicine Market Size by End-User 196
16. TOP COMPANY PROFILES 197
16.1 Hoffmann La Roche 197
16.1.1 Key Facts 197
16.1.2 Business Description 198
16.1.3 Hoffmann La Roche, Timeline 198
16.1.4 Key Product/Services Offerings 199
16.1.5 Growth Strategy 200
16.1.6 SWOT Analysis 201
16.1.7 Key Financials 202
16.1.7.1 Revenue Split 203
16.1.8 Recent Developments 203
16.1.8.1 Product Launch 203
16.1.8.2 Partnerships 205
16.1.8.3 Mergers and Acquisitions 206
16.2 Abbott Laboratories 207
16.2.1 Key Facts 207
16.2.2 Business Description 207
16.2.3 Abbott Laboratories, Timeline 208
16.2.4 Key Product/Services Offerings 208
16.2.5 Growth Strategy 209
16.2.6 SWOT Analysis 210
16.2.7 Key Financials 211
16.2.7.1 Revenue Split 212
16.2.8 Recent Developments 212
16.2.8.1 Product Launch 212
16.2.8.2 Partnerships 213
16.3 AstraZeneca 216
16.3.1 Key Facts 216
16.3.2 Business Description 217
16.3.3 AstraZeneca, Timeline 217
16.3.4 Key Product/Services Offerings 217
16.3.5 Growth Strategy 218
16.3.6 SWOT Analysis 220
16.3.7 Key Financials 221
16.3.7.1 Revenue Split 222
16.3.8 Recent Developments 222
16.3.8.1 Product Launch 222
16.3.8.2 Business Expansion, Investment, and Divestitures 223
16.4 Eli Lilly and Company 224
16.4.1 Key Facts 224
16.4.2 Business Description 225
16.4.3 Eli Lilly and Company, Timeline 225
16.4.4 Key Product/Services Offerings 225
16.4.5 Growth Strategy 226
16.4.6 SWOT Analysis 227
16.4.7 Key Financials 228
16.4.7.1 Revenue Split 229
16.4.8 Recent Developments 229
16.4.8.1 Product Launch 229
16.4.8.2 Partnerships 229
16.4.8.3 Mergers and Acquisitions 230
16.5 NanoString Technologies 231
16.5.1 Key Facts 231
16.5.2 Business Description 232
16.5.3 NanoString Technologies, Timeline 232
16.5.4 Key Product/Services Offerings 232
16.5.5 Growth Strategy 233
16.5.6 SWOT Analysis 234
16.5.7 Key Financials 235
16.5.7.1 Revenue Split 236
16.5.8 Recent Developments 236
16.5.8.1 Product Launch 236
16.5.8.2 Partnerships 237
16.6 NeoGenomics Laboratories 238
16.6.1 Key Facts 238
16.6.2 Business Description 239
16.6.3 Key Product/Services Offerings 239
16.6.4 Growth Strategy 239
16.6.5 SWOT Analysis 240
16.6.6 Key Financials 241
16.6.6.1 Revenue Split, by Region and Segment 242
16.6.7 Recent Developments 242
16.6.7.1 Product Launches 242
16.6.7.2 Partnerships 243
16.6.7.3 Business Expansions and Investment 243
16.6.7.4 Mergers and Acquisitions 243
16.7 Novartis AG 244
16.7.1 Key Facts 244
16.7.2 Business Description 244
16.7.3 Key Product/Services Offerings 245
16.7.4 Growth Strategy 246
16.7.5 SWOT Analysis 247
16.7.6 Key Financials 248
16.7.6.1 Revenue Split, by Region and Segment 249
16.7.7 Recent Developments 249
16.7.7.1 Product Launches 249
16.7.7.2 Partnerships 250
16.7.7.3 Mergers and Acquisitions 250
16.8 Teva Pharmaceutical Industries Limited 251
16.8.1 Key Facts 251
16.8.2 Business Description 251
16.8.3 Key Product/Services Offerings 252
16.8.4 Growth Strategy 253
16.8.5 SWOT Analysis 254
16.8.6 Key Financials 255
16.8.6.1 Revenue Split, by Region and Segment 256
16.8.7 Recent Developments 256
16.8.7.1 Product Launches 256
16.8.7.2 Business Expansions and Investment 257
16.8.7.3 Mergers and Acquisitions 258
16.9 Thermo Fisher Scientific 259
16.9.1 Key Facts 259
16.9.2 Business Description 259
16.9.3 Key Product/Services Offerings 260
16.9.4 Growth Strategy 260
16.9.5 SWOT Analysis 261
16.9.6 Key Financials 262
16.9.6.1 Revenue Split, by Region and Segment 263
16.9.7 Recent Developments 263
16.9.7.1 Product Launches 263
16.9.7.2 Partnerships 264
16.9.7.3 Business Expansions and Investment 264
16.9.7.4 Mergers and Acquisitions 264
16.10 Quest Diagnostics 265
16.10.1 Key Facts 265
16.10.2 Business Description 265
16.10.3 Key Product/Services Offerings 266
16.10.4 Growth Strategy 266
16.10.5 SWOT Analysis 268
16.10.6 Key Financials 269
16.10.6.1 Revenue Split, by Region and Segment 270
16.10.7 Recent Developments 270
16.10.7.1 Product Launches 270
16.10.7.2 Partnerships 270
16.10.7.3 Business Expansions and Investment 271
16.10.7.4 Mergers and Acquisitions 271
TABLE 2 Next-Generation Sequencing- Based Tumor-Profiling Multiplex Gene Panels 59
TABLE 3 Requirements for Core Hospitals 60
TABLE 4 Top Product Launches 66
TABLE 5 Top Business Partnerships 72
TABLE 6 Top, Business Expansion, Investment, and Divestitures 75
TABLE 7 Top Mergers and Acquisitions 77
TABLE 8 Precision Medicine Drugs approved by the FDA in 2017 90
TABLE 9 Companion Diagnostic markers required by FDA. Testing is required before deciding on therapeutic drug use 94
TABLE 10 Statistical Learning Approach to Precision Cardiology 112
TABLE 11 Hoffmann La Roche Key Facts 197
TABLE 12 Hoffmann La Roche, Ownership Structure 197
TABLE 13 Products segmentation of Hoffmann La Roche 199
TABLE 14 Hoffmann La Roche Growth Strategy 200
TABLE 15 Hoffmann La Roche, Product Launches 203
TABLE 16 Hoffmann La Roche, Partnerships 205
TABLE 17 Hoffmann La Roche Mergers and Acquisitions 206
TABLE 18 Abbott Laboratories Key Facts 207
TABLE 19 Abbott Laboratories, Ownership Structure 207
TABLE 20 Products segmentation of Abbott Laboratories 208
TABLE 21 Abbott Laboratories Growth Strategy 209
TABLE 22 Abbott Laboratories, Product Launches 212
TABLE 23 Abbott Laboratories, Partnerships 213
TABLE 24 AstraZeneca Key Facts 216
TABLE 25 AstraZeneca, Ownership Structure 216
TABLE 26 Products segmentation of AstraZeneca 217
TABLE 27 AstraZeneca Growth Strategy 218
TABLE 28 AstraZeneca, Product Launches 222
TABLE 29 AstraZeneca, Business Expansion, Investment, and Divestitures 223
TABLE 30 Eli Lilly and Company Key Facts 224
TABLE 31 Eli Lilly and Company, Ownership Structure 224
TABLE 32 Products segmentation of Eli Lilly and Company 225
TABLE 33 Eli Lilly and Company Growth Strategy 226
TABLE 34 Eli Lilly and Company, Product Launches 229
TABLE 35 Eli Lilly and Company, Partnerships 229
TABLE 36 Eli Lilly and Company, Mergers and Acquisitions 230
TABLE 37 NanoString Technologies Key Facts 231
TABLE 38 NanoString Technologies, Ownership Structure 231
TABLE 39 Products segmentation of NanoString Technologies 232
TABLE 40 NanoString Technologies Growth Strategy 233
TABLE 41 NanoString Technologies, Product Launches 236
TABLE 42 NanoString Technologies, Partnerships 237
TABLE 43 NeoGenomics Laboratories Key Facts 238
TABLE 44 NeoGenomics Laboratories Ownership Structure 238
TABLE 45 The product segmentation of NeoGenomics Laboratories 239
TABLE 46 NeoGenomics Laboratories Growth Strategy 239
TABLE 47 NeoGenomics Laboratories Product Launches 242
TABLE 48 NeoGenomics Laboratories Partnerships 243
TABLE 49 NeoGenomics Laboratories Business Expansions, Investment, and Divestitures 243
TABLE 50 NeoGenomics Laboratories Mergers and Acquisitions 243
TABLE 51 Novartis AG Key Facts 244
TABLE 52 Novartis International AG Ownership Structure 244
TABLE 53 The product segmentation of Novartis AG 245
TABLE 54 Novartis AG Growth Strategy 246
TABLE 55 Novartis AG Product Launches 249
TABLE 56 Novartis AG Partnerships 250
TABLE 57 Novartis AG Mergers and Acquisitions 250
TABLE 58 Teva Pharmaceutical Industries Limited Key Facts 251
TABLE 59 Teva Pharmaceutical Industries Limited Ownership Structure 251
TABLE 60 Product segmentation of Teva Pharmaceutical Industries Limited 252
TABLE 61 Teva Pharmaceutical Industries Limited Growth Strategy 253
TABLE 62 Teva Pharmaceutical Industries Limited Product Launches 256
TABLE 63 Teva Pharmaceutical Industries Limited Business Expansions, Investment, and Divestitures 257
TABLE 64 Teva Pharmaceutical Industries Limited Mergers and Acquisitions 258
TABLE 65 Thermo Fisher Scientific Key Facts 259
TABLE 66 Thermo Fisher Scientific Ownership Structure 259
TABLE 67 Thermo Fisher Scientific, Product/Services Offerings 260
TABLE 68 Thermo Fisher Scientific Growth Strategy 260
TABLE 69 Thermo Fisher Scientific Product Launches 264
TABLE 70 Thermo Fisher Scientific Partnerships 265
TABLE 71 Thermo Fisher Scientific Business Expansions, Investment, and Divestitures 265
TABLE 72 Thermo Fisher Scientific Mergers and Acquisitions 265
TABLE 73 Quest Diagnostics Key Facts 266
TABLE 74 Quest Diagnostics Ownership Structure 266
TABLE 75 The product segmentation of Quest Diagnostics 267
TABLE 76 Quest Diagnostics Growth Strategy 267
TABLE 77 Quest Diagnostics Product Launches 271
TABLE 78 Quest Diagnostics Partnerships 271
TABLE 79 Quest Diagnostics Business Expansions, Investment, and Divestitures 272
TABLE 80 Quest Diagnostics Mergers and Acquisitions 272
Similar Reports
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
- Publish Date: November 14, 2017
- $5370
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
- Publish Date: July 20, 2017
- $5370
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...
- Publish Date: April 24, 2017
- $5370
